Based on 2 analysts offering 12 month price targets for Vivos Therapeutics Inc
Min Forecast
$5.50+239.51%
Avg Forecast
$6.25+285.8%
Max Forecast
$7.00+332.1%
Should I buy or sell VVOS stock?
Based on 2 analysts offering ratings for Vivos Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VVOS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VVOS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More
Be the first to know when Wall Street analysts revise their VVOS stock forecasts and price targets.
Is Vivos Therapeutics Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: VVOS) stock is to Buy VVOS stock.
Out of 2 analysts, 0 (0%) are recommending VVOS as a Strong Buy, 2 (100%) are recommending VVOS as a Buy, 0 (0%) are recommending VVOS as a Hold, 0 (0%) are recommending VVOS as a Sell, and 0 (0%) are recommending VVOS as a Strong Sell.
What is VVOS's earnings growth forecast for 2026-2026?
(NASDAQ: VVOS) Vivos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Vivos Therapeutics's earnings in 2026 is -$17,104,000.
In 2026, VVOS is forecast to generate -$11,459,835 in earnings, with the lowest earnings forecast at -$15,062,268 and the highest earnings forecast at -$8,021,885.
What is VVOS's revenue growth forecast for 2026-2026?
(NASDAQ: VVOS) Vivos Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Vivos Therapeutics's revenue in 2026 is $17,317,000.
In 2026, VVOS is forecast to generate $258,875,429 in revenue, with the lowest revenue forecast at $202,591,909 and the highest revenue forecast at $297,281,606.
What is VVOS's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: VVOS) forecast ROA is -44.69%, which is lower than the forecast US Medical Devices industry average of 10.05%.
What is VVOS's Price Target?
According to 2 Wall Street analysts that have issued a 1 year VVOS price target, the average VVOS price target is $6.25, with the highest VVOS stock price forecast at $7.00 and the lowest VVOS stock price forecast at $5.50.
On average, Wall Street analysts predict that Vivos Therapeutics's share price could reach $6.25 by Dec 3, 2026. The average Vivos Therapeutics stock price prediction forecasts a potential upside of 285.8% from the current VVOS share price of $1.62.
What is VVOS's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: VVOS) Vivos Therapeutics's current Earnings Per Share (EPS) is -$1.77. In 2026, VVOS's EPS is forecast to hit -$1.28 (min: -$1.68, max: -$0.89).
What is VVOS's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: VVOS) forecast ROE is -452.6%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.